Brief: Intervacc AB And Dechra Pharmaceuticals Enter Into An Agreement To Commercialize Strangvac In Europe

Intervacc AB

12/04/2021 20:21

April 12 (Reuters) - Intervacc Ab  IVACC.ST :
    * AND DECHRA PHARMACEUTICALS PLC ENTER INTO AN AGREEMENT TO
COMMERCIALIZE STRANGVAC IN EUROPE
    * AGREEMENT WILL RUN FOR A PERIOD OF FIVE YEARS AND
INTERVACC WILL
REMAIN MARKET AUTHORIZATION HOLDER FOR STRANGVAC IN EUROPE
    * INTERVACC - STRANGVAC IS IN LATE-STAGE REGULATORY REVIEW
WITH
EUROPEAN MEDICINES AGENCY
    * CURRENTLY WORKING WITH EUROPEAN MEDICAL AGENCY SEEKING
APPROVAL
FOR STRANGVAC IN EUROPE AND IS FORECASTING APPROVAL IN Q2 OF
2021

Source text for Eikon:  ID:nWkr1dqQWj 
Further company coverage:  IVACC.ST 

 ((Reuters.Briefs@thomsonreuters.com;))